OOIR: Observatory of International Research

Papers

(The median citation count of Annals of the Rheumatic Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia	951
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat	584
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?	536
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al	446
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19	343
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block	327
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	327
POS0993 ELEVATED INTRACELLULAR IFN SIGNALING BY T AND B CELLS BUT UNALTERED B CELL DISTRIBUTION IS A CHARACTERISTIC OF ANTI-SSA POSITIVE ASYMPTOMATIC WOMEN AT-RISK FOR CONGENITAL HEART BLOCK	313
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIAL	309
OP0057 EVALUATION OF SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT	306
POS0389 LOW INCIDENCE OF LATE-ONSET GCA DURING THE FIRST YEAR IN PATIENTS WITH POLYMYALGIA RHEUMATICA — AN IMAGING-BASED STUDY	262
AB0372 PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA	262
POS1021 THE EFFECT OF CANNABIDIOL ON QUANTITATIVE SENSORY TESTING PARAMETERS IN PATIENTS WITH HAND OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	238
POS1430 WATCH OUT FOR THE INFLAMMATORY RESPONSE IN AUTOIMMUNE DISEASES WITH INTERSTITIAL PNEUMONIA. A RETROSPECTIVE STUDY	237
POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA	232
POS1035 FORCED VITAL CAPACITY TRAJECTORIES AND RISK OF LUNG TRANSPLANT AND ILD-RELATED MORTALITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	220
AB0503 SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT	218
POS1478-HPR ANALYSIS OF MEDICATION USAGE AND MONTHLY COSTS IN HOSPITALIZED PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY	218
AB0738 EXPRESSION AND ROLE OF THE LNCRNA RP11-184M15.1 IN THE MYELOID COMPARTMENT DURING INFLAMMATION	206
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY	201
AB1016 SERUM CXCL-13 LEVELS ARE ASSOCIATED WITH ACTIVE NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	196
AB1151 CIRCULATING CTHRC1 LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND PREDICT SURVIVAL IN SYSTEMIC SCLEROSIS	193
AB1598-HPR MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES	173
AB1649-PARE BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE FOR IgG4-RELATED DISEASE: DATA FROM A LARGE COHORT OF ITALIAN PATIENTS	170
OP0120 EFFECTIVENESS AND COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPONDYLOARTHRITIS (TeleSpA-STUDY): A PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED	169

AB0661 TOFACITINIB PLUS IGURATIMOD IN RHEUMATOID ARTHRITIS-RELATED PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE: 13 CASES FROM A SINGLE CENTRE IN CHINA	167
AB0462 ONE-YEAR RETENTION RATE OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. DATA OF THE SPANISH BIOBADASER REGISTRY	166
AB0943 ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS	162
AB0916 EFFECTIVENESS OF A PERSONALIZED PHYSICAL TRAINING PROGRAM ON DISEASE ACTIVITY AND AEROBIC CAPACITY IN axSpA: A RANDOMIZED CONTROLLED STUDY	154
AB0666 CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS	154
OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSI	147
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY	144
AB0732 CELLULAR AND MOLECULAR HALLMARKS OF EARLY METHOTREXATE RESPONSE IN RA	143
POS0071 IMMUNOMODULATORY TREATMENT AND IMMUNE RESPONSES TO COVID-19 BOOSTER SHOTS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINE RESPONSE IN RHEUMATOLOGY PATIENTS (C	140
POS0283 DISEASE - CHARACTERISTIC CHANGES CAN ALREADY BE FOUND IN INDIVIDUALS AT RISK OF SJÖGREN’S SYNDROME – RESULTS OF THE preSStige STUDY	140
POS0344 PAROTID TRANSCRIPTOMIC NETWORKS ASSOCIATED WITH B CELL HYPERACTIVITY, AND VIRUS/IFN ACTIVITY ARE TARGETED BY LEFLUNOMIDE/HYDROXYCHLOROQUINE THERAPY IN SJÖGREN PATIENTS AND ARE CAPTURED BY A CI	137
AB0394 COMORBIDITIES IN 40.643 PSORIATIC ARTHRITIS PATIENTS ACCORDING TO GENDER: RESULTS FROM E.PULSE, THE NATIONWIDE HEALTH DATA	134
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS	133
POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRAL OF PATIENTS WITH LOW LIKELIHOOD OF AN INFLAMMATORY RHEUMATIC DISEASE	131
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	124
AB1272 MANAGING OF ANCA-ASSOCIATED VASCULITIS: ADHERENCE TO TREATMENT GUIDELINES AND EARLY MODIFICATIONS, ARE WE THERE YET?	121
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY	117
POS0878 INFERTILITY AND THE CHANCE OF SUCCESSFUL ASSISTED REPRODUCTION TREATMENTS IN CHILDBEARING WOMEN WITH RHEUMATIC DISEASES	115
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT	112
POS0349 SINGLE OSTEOCLAST RESORPTION ANALYSIS REVEALS AN INCREASED INTRINSIC OSTEOCLAST ACTIVITY IN RA PATIENTS	111
POS1220 MODULATING INFLAMMATION IN AN ADVANCED 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUE INCORPORATING FIBROBLASTS, ENDOTHELIAL CELLS AND MACROPHAGES	110
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT	108
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS	107
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY	106
AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture	104
AB0928 CHARACTERISTICS OF AXIAL PSORIATIC ARTHRITIS PATIENTS WITH SYMMETRICAL AND ASYMMETRICAL SACROILIITIS	101
AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS	99
AB0777 Influence of TNF inhibitors on subclinical atherosclerosis in Spondyloarthritis patients	99
AB1025 TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPONDYLOARTHRITIS	99
AB1127 ANTIOSTEOPOROTIC TREATMENT AND COVID-19 RISK: IS THERE AN ASSOCIATION?	97
AB1134 BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS	97
AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY	95
AB0878 Higher vitamin D serum level is associated with a better clinical response to bDMARDs in patients with axial spondyloarthritis.	94
POS1566-PARE BEYOND MEDICATION – SELF MANAGEMENT AS A COMPLEMENTARY APPROACH FOR TREATING RMDS	93
POS1526-HPR WHICH FACTORS INFLUENCE PATIENTS' PREFERENCES FOR TELEHEALTH APPLICATIONS IN RHEUMATIC DISEASES? A QUALITATIVE STUDY	91
OP0128 ADHERENCE TO MEDICATIONS DURING PREGNANCY IN SYSTEMIC AUTOIMMUNE DISEASE	90
POS0740 IMPACT OF TIME TO REMISSION, FLARES AND EXPOSURE TO IMMUNOSUPPRESSIVES ON THE DEVELOPMENT OF ADVANCED CHRONIC KIDNEY DISEASE (STAGE IV OR WORSE) IN LUPUS NEPHRITIS	90
POS0851 FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS	89
POS0959 IMPACT OF INITIATION OF TARGETED THERAPY ON THE USE OF ASSOCIATED TREATMENTS AND HEALTHCARE CONSUMPTION IN PSORIATIC ARTHRITIS: A COHORT STUDY OF 9,793 PATIENTS FROM THE FRENCH HEALTH INSURANC	88
POS1216 NIEMANN-PICK PROTEINS TYPE C2 DRIVES PROINFLAMMATORY PROPERTIES OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS THROUGH MEDIATING CHOLESTEROL METABOLIC REPROGRAMMING	87
POS0115 EOSINOPHILIC GIANT CELL ARTERITIS: A DIFFERENT SUBSET OF DISEASE?	85
AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK	85
AB0251 CLINICAL FEATURES OF KOREAN PATIENTS WITH ANTI-SRP ANTIBODY-ASSOCIATED IMMUNE-MEDIATED NECROTIZING MYOPATHY	82
POS1107 IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF 2 DOSES OF AN ADJUVANTED HERPES ZOSTER SUBUNIT VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CLINICAL TRIAL	82
POS0813 PREDICTORS OF RESPONSE TO bDMARDs AND tsDMARDs THERAPY: THE ROLE OF MUSCULOSKELETAL ULTRASOUND AND POTENTIAL NEW BIOMARKERS	81
AB1320 DOPPLER ULTRASOUND IN GIANT CELL ARTERITIS: WHICH TERRITORIES SHOULD WE EXPLORE? A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE	80
AB0482 PREVALENCE AND SEVERITY OF MAFLD IN PSORIATIC DISEASE: ARE WE MISSING SOMETHING?	80
POS1108 SUBCLINICAL ATHEROSCLEROSIS IS ASSOCIATED WITH FUTURE CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AT APPARENT LOW RISK FOR CARDIOVASCULAR DISEASE: A LONGITUDINAL PROSPECTIVE	79
AB1323 ALL WALES GCA AUDIT 2023-A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE GCA CARE ACROSS WALES	79
AB0529 JAK-INHIBITORS PROMOTE INSULIN SENSITIVITY AND ENHANCE IMMUNOSUPPRESSIVE EFFECT OF INSULIN ON CD4+ T CELLS OF PATIENTS WITH RHEUMATOID ARTHRITIS	79

AB1535 A PROFILE OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SARD-PAH) FROM WESTERN INDIA: A SINGLE CENTRE RETROSPECTIVE STUDY	78
POS0866 LARGE-VESSEL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS: A MULTICENTER CASE-CONTROL STUDY	77
POS0118-PARE THE RAIISE SCHOOL PACK FOR TEACHERS SUPPORTING CHILDREN AND YOUNG PEOPLE WITH INVISIBLE ILLNESSES IN SCHOOL: A MULTI-STAKEHOLDER CO-CREATION PROCESS	77
AB0445 EVALUATION OF SUBCLINICAL BOWEL INFLAMMATION USING FAECAL CALPROTECTIN LEVEL IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS – A PILOT STUDY	77
POS0449 GENE THERAPY WITH INTERFERENCE miRNAs AS A NEW ALTERNATIVE FOR DISCOID CUTANEOUS LUPUS (DLE)	77
AB0393 MUSCULOSKELETAL MANIFESTATIONS IN PATIENTS DIAGNOSED WITH MARFAN SYNDROME	77
AB0102 DIFFERENTIAL EXPRESSION OF ORTHOLOGUE GENES INVOLVED IN GLYCINE AND PYRUVATE METABOLISM CHARACTERIZE THE GUT MICROBIOME META-TRANSCRIPTOME OF SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA AND GOUT	77
AB0255 DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS WITH JUVENILE DERMATOMYOSITIS UNDER FOLLOW-UP IN THE ADULT RHEUMATOLOGY OFFICE	76
AB1233 ROLE OF HEMATOLOGICAL INDICES IN SYSTEMIC SCLEROSIS: USE AS A PREDICTOR OF SUBCLINICAL VASCULAR DAMAGE, CARDIOVASCULAR EVENTS AND DEATH	76
OP0214 ASSOCIATIONS OF REMNANT CHOLESTEROL WITH ALL-CAUSE AND CAUSE-SPECIFIC THROMBOTIC RISK IN INDIVIDUALS WITH ANTIPHOSPHOLIPID SYNDROME	76
POS0594 NEW INSIGHTS INTO EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS SUBTYPES THROUGH SEROLOGIC BIOMARKER PROFILING – RESULTS FROM THE SCANDRA PROJECT	76
AB0085 PRE-EXPOSURE PROPHYLAXIS OF SARS-COV-2 INFECTION AND SEVERE COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB AT RISK OF SEVERE COVID-19: EFFI	75
POS0307 CENTRAL SENSITIVITY SYNDROME AFFECTS THE TREATMENT SATISFACTION IN PATIENTS WITH RHEUMATOID ARTHRITIS	74
AB1419 CLINICAL ANALYSIS OF FOUR CASES OF PACHYDERMOPERIOSTOSIS	72
AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY	71
AB0857 ASSOCIATIONS AMONG PATIENT EMPOWERMENT, PATIENT ENGAGEMENT, PATIENT ACTIVATION AND CLINICAL MANIFESTATIONS IN PRIMARY SJÖGREN’S SYNDROME	71
AB1294 EFFICACY AND SAFETY OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN THE TREATMENT OF TAKAYASU ARTERITIS	71
AB1732 PROFILE OF MULTISYSTEM INFLAMMATORY SYNDROME (MIS-C) IN INFANTS DURING THE SECOND WAVE OF SARS-CoV-2 PANDEMIC: AN OBSERVATIONAL CROSS-SECTIONAL STUDY	71
AB0610 EARLY RHEUMATOID ARTHRITIS AND THYROID DYSFUNCTION: A 20-YEARS FOLLOW-UP STUDY IN BULGARIA	71
AB1636-HPR SOCIAL MEDIA USE BY PHYSIOTHERAPISTS, OCCUPATIONAL THERAPISTS AND ALLIED HEALTHCARE PROFESSIONALS IN KAZAKHSTAN	70
AB1285 ACUTE BRACHIAL PLEXITIS IN GIANT CELL ARTERITIS A CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE	69
AB0847 KIDNEY INVOLVEMENT AND PROGRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ISOLATED SJÖGREN’S SYNDROME	69
AB0294 VITAMIN D LEVEL AND LOCOMOTIVE FUNCTIONS IN WOMEN WITH RHEUMATOID ARTHRITIS	67
POS1537-HPR PERCEIVED BARRIERS AND FACILITATORS TO PHYSICAL ACTIVITY AND ITS ASSOCIATED FACTORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS	67
AB1365 SKELETAL METASTASES OF DIGESTIVE ORIGIN IN RHEUMATOLOGY: A DESCRIPTIVE STUDY OF 18 CASES	67
AB0881 Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in Patients With Active Psoriatic Arthritis Through 2 Years of DISCOVER-2	66
POS1338 CENTRAL SENSITIZATION AND RELATED FACTORS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER	65
AB0526 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING SF-36 SCALE	65
AB0273 IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS	65
AB0347 TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK	64
POS0946 THE COURSE OF BONE MINERAL DENSITY DURING 8 YEARS OF TREATMENT WITH TNF-α INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS	64
AB1040 ASSOCIATION OF Q141K POLYMORPHISM OF ABCG2 GENE WITH THE EFFECTIVENESS OF URATE-LOWERING THERAPY IN PATIENTS WITH GOUT (PILOT STUDY)	64
POS0619 CLINICAL AND SUBCLINICAL INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS: ASSOCIATED FACTORS.	64
POS1384 NON-INVASIVE IN VIVO METABOLIC PROFILING OF INFLAMMATION IN JOINTS AND ENTHESES BY OPTOACOUSTIC IMAGING	64
AB0963 Frequency of sexual dysfunction in psoriatic arthritis, Santo Domingo, Dominican Republic	63
OP0015 PROINFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMYALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF	63
AB0245 PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS AND SECONDARY SJÖGREN SYNDROME	63
POS0405 INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES	62
OP0252 FACTORS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY	62
POS0061 INTERCEPTION OF THE DEVELOPMENT OF RHEUMATOID ARTHRITIS BY A 1-YEAR COURSE OF METHOTREXATE IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RHEUMATOID ARTHRITIS: 4 YEAR RESULTS OF TH	61
POS0334 DAPIROLIZUMAB PEGOL IMPACTS IMPORTANT IMMUNOLOGIC PATHWAYS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PHARMACODYNAMIC ANALYSIS OF B CELL AND TYPE I INTERFERON PATHWAYS FROM A PHASE 2B TRIAL	61
POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS	60
POS0226 GRANULOMATOSIS WITH POLYANGIITIS AND COURSE OF PREGNANCY - RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS	60
POS1087 THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH bDMARDs	60
POS0615 IS DMARD-FREE REMISSION IMPOSSIBLE FOR ALL RHEUMATOID ARTHRITIS PATIENTS OR ONLY FOR THOSE REQUIRING BIOLOGICALS?	60
AB0032 ASSESSMENT OF AUTONOMIC DYSFUNCTION AND ITS RELATIONS WITH CLINICAL PARAMETERS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	60
POS0755 SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A SINGLE ORALLY ADMINISTERED DOSE OF ENPATORAN IN A PHASE I STUDY OF HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS	59
POS0756 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HR-QoL) ACROSS THE SPECTRUM OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE LEAP COHORT	59
OP0177 IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 mRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER	59
POS0846 MORTALITY OUTCOME OF ACUTE MYOCARDIAL INFRACTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES, A QUALITATIVE APPROACH ANALYSIS OF THE NATIONAL INPATIENT SAMPLE FROM 2016-2019	58
POS0452 ABNORMALITY OF TYPE I INTERFERON SIGNALLING IN B CELLS IN PRIMARY SJÖGREN´S SYNDROME AND THE IMPACT ON LABORATORY AND CLINICAL FINDINGS	58
POS0400 MODULATION OF HUMAN EARLY B CELL DEVELOPMENT THROUGH TARGETED DEGRADATION OF IKAROS AND AIOLOS WITH IBERDOMIDE	58
OP0055 THE COMPARISON OF EFFECTS OF TWO DIFFERENT EXERCISE PROGRAM ON FUNCTIONAL CAPASITY AND QUALITY OF LIFE IN PREGNANT WOMEN WITH LOW BACK PAIN	58
OP0208-HPR EFFECT OF AN 8-WEEK SPECIALIZED PHYSICAL THERAPY PROGRAM ON SEXUAL HEALTH IN FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY	58
POS0984 PREVALENCE OF axSpA IN PATIENTS TREATED FOR CHRONIC BACK PAIN IN CHIROPRACTIC CLINICS: THE OREGON CHIROPRACTIC AXIAL SPONDYLOARTHRITIS STUDY (ORCAS) – AN INTERIM ANALYSIS	57
POS0790 18F-FLUORODEOXYGLUCOSE (FDG) PET-CT IMAGING OF SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME AND ITS CORRELATION WITH ULTRASONOGRAPHIC SCORES AND SALIVARY FLOW RATE COMPARED TO HEALTHY CONTROL	57
POS0730 A BETTER SELF-EFFICACY IS PREDICTIVE OF BETTER HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. DATA FROM A LATIN AMERICAN MESTIZO COHORT	57
POS0148 SPARCC, MASES, LEI AND MEI INDEXES CAPTURE DIFFERENT PATIENTS WITH ENTHESITIS IN AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS.	56
POS0113 THE PREDICTIVE VALUE OF HEALTH LITERACY ON DISEASE ACTIVITY AND MEDICATION USE OVER TIME IN RHEUMATOID ARTHRITIS PATIENTS.	56
POS1066 DEVELOPMENT OF PHYSICAL AND MENTAL COMPONENT SUMMARY SCORES FROM PROMIS-29 INSTRUMENT IN PATIENTS WITH PSORIATIC ARTHRITIS	56
POS0365 RELAPSES ARE COMMON ΙΝ SEVERE HEMATOLOGICAL SLE: REAL-LIFE EXPERIENCE FROM THE “ATTIKON” LUPUS COHORT	55
OP0132 PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING	55
POS0541 PREDICTORS OF REMISSION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH UPADACITINIB OR ADALIMUMAB IN THE SELECT-COMPARE PHASE 3 STUDY: CLINICAL STATUS AT WEEK 12, BUT NOT STANDARD LABORATORY ME	55
AB1076 IS THERE AN ADDITIONAL IMPACT OF STIMULATING CD8+ LYMPHOCYTES TO DETECT LATENT TUBERCULOSIS IN PATIENTS WITH RHEUMATIC DISEASES?	55
OP0080 STAT3 DEGRADERS INHIBIT Th17 DEVELOPMENT AND CYTOKINE PRODUCTION RESULTING IN PROFOUND INHIBITION OF COLLAGEN-INDUCED AUTOIMMUNE MURINE ARTHRITIS	55
AB0240 CORRELATION BETWEEN KLOTHO LEVELS AND ANKLE-BRACHIAL INDEX IN FEMALE RHEUMATOID ARTHRITIS PATIENTS	54
AB1439 IS THERE AN INCREASED PREVALENCE OF DIABETES MELLITUS IN THE AXIAL SPONDYLOARTHROPATHY PATIENT GROUP: A REVIEW FROM A UK TEACHING HOSPITAL SPONDYLOARTHROPATHY SERVICE	54
POS1540-HPR CENTRAL SENSITIZATION PLAYS A PROMINENT ROLE IN DISEASE ACTIVITY, FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE IN PATIENTS WITH SPONDYLOARTHRITIS.	54
AB0230 THE INFLUENCE OF THE PATIENT'S PSYCHOLOGICAL STATUS ON THE INFLAMMATORY ACTIVITY OF RHEUMATOID ARTHRITIS	54
AB0371 CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).	53
AB0764 Factors associated with remission after gradual decline of TNFi in spondyloarthritis	53
AB0362 NEUTROPHIL COUNT REDUCTION 1 MONTH AFTER INITIATING SARILUMAB AND BASELINE SERUM SOLUBLE gp130 LEVELS CAN INDEPENDENTLY PREDICT CLINICAL REMISSION WITHIN 3 MONTH IN RHEUMATOID ARTHRITIS PATIENT	52
AB1468 ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY	51
AB0229 ACHIEVING GLUCOCORTICOID FREE MIGHT DECREASE RISK FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - TEN-YEAR FINDINGS FROM THE TOMORROW STUDY	51
AB1133 MUSCULOSKELETAL MANIFESTATIONS AMONG PATIENTS WITH COVID-19 INFECTION	51
AB1012 MANAGEMENT OF BREAST CANCER TREATMENT INDUCED BONE LOSS- RE-AUDIT	51
AB1494 THE QUALITY OF REPORTING IN RANDOMIZED CONTROLLED TRIALS OF BALANCE EXERCISES IN TOTAL KNEE ARTHROPLASTY	51
AB0476 PREDICTIVE FACTORS FOR THE DEVELOPMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA	51
POS1270 COVID19 VACCINATION IN PATIENTS WITH AXIAL AND PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: ADVERSE EVENTS AND IMPACT ON DISEASE ACTIVITY	50
Time to treat the climate and nature crisis as one indivisible global health emergency	50

POS1248 URIC ACID AND COVID-19: PATTERN OF CHANGES AND ASSOCIATION WITH PROGNOSIS	50
POS1106 MEDIATORS OF THE EFFECT OF THERAPEUTIC EXERCISE ON PAIN AND FUNCTION IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS; AN INDIVIDUAL PATIENT DATA MEDIATION STUDY FROM THE OA TRIAL BANK.	50
Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial	50
POS1501-HPR ADDRESSING THE VOCATIONAL DEVELOPMENT OF YOUNG PEOPLE WITH LONG-TERM HEALTH CONDITIONS IN HEALTH CARE SETTINGS: A SYSTEMATIC REVIEW AND MIXED METHODS SYNTHESIS	50
POS1198 VACCINATION AGAINST COVID-19 SHOULD BE ENCOURAGED IN PATIENTS WITH RHEUMATIC DISEASE, AS MOST PATIENTS DEVELOP A SEROLOGICAL RESPONSE AGAINST THE VACCINE AND VACCINATION REDUCES SELF-IMPOSED I	50
POS0718 SIROLIMUS MONOTHERAPY FOR THROMBOCYTOPENIA IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: A PILOT STUDY FROM A TERTIARY REFERRAL CENTER	50
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus	49
POS0877 INTERSTITIAL LUNG DISEASE IN ANTI-U1RNP SYSTEMIC SCLEROSIS PATIENTS: A EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) ANALYSIS	49
OP0372-PARE Beyond the Doctor's Office: The School and Workplace Needs of Young People Living with Rheumatic Disease	48
ABS0438 ASSOCIATIONS AND RISK FACTORS FOR FREQUENT ORAL ANALGESIC USE IN LOWER LIMB OSTEOARTHRITIS	48
POS0527 Distinct cardiac phenotypes identified by cardiovascular magnetic resonance in treatment-naïve rheumatoid arthritis: a cluster analysis	48
OP0215 SPATIAL TRANSCRIPTOMICS OF SKIN BIOPSIES FROM VERY EARLY SYSTEMIC SCLEROSIS UNVEILS EARLY DRIVERS OF SKIN FIBROSIS WITHIN THE EPIDERMIS	48
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?	48
POS1066 AN ALTERED IMMUNOMETABOLIC PROFILE CHARACTERIZES B CELLS OF PATIENTS WITH OLIGOARTICULAR- AND POLYARTICULAR- JUVENILE IDIOPATHIC ARTHRITIS	48
POS0007 Reduced Follicular Helper T cells in Peripheral Blood Marks a Distinct Feature of Retroperitoneal Fibrosis	48
ABS0959 EVALUATION OF MULTIMODAL REHABILITATION AND ITS IMPACT ON COMORBIDITIES AND RISK FACTORS FOR THE TREATMENT OF KNEE PAIN AND IMPROVEMENT OF QUALITY OF LIFE IN EARLY OSTEOARTHRITIS: THE AKAPP ST	48
ABS0015 SKIN MICROBIOME SHOWS DIFFERENCES BETWEEN PATHERGY POSITIVE AND NEGATIVE PATIENTS WITH BEHÇET'S SYNDROME	47
ABS0047 MATERNAL AND NEONATAL ANTI-RO52, ANTI-RO60 AND ANTI-LA LEVELS CORRELATE WITH INTERFERON SCORES	47
POS1337 CLINICAL OUTCOMES OF METHOTREXATE TREATMENT FOR IMMUNE CHECKPOINT INHIBITOR-INDUCED ARTHRITIS IN CANCER PATIENTS: A RETROSPECTIVE LONGITUDINAL PILOT STUDY	47
ABS1063 THE MANY FACES OF WHIPPLE'S DISEASE	47
POS1118 CLINICAL SIGNIFICANCE OF NON-INFECTIOUS PROCALCITONIN ELEVATION IN THE COURSE OF STILL'S DISEASE	47
ABS0665 CORRELATION BETWEEN Ro52 ANTIBODY POSITIVITY AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY	46
ABS0350 LONG-TERM CHANGES IN PARAMETERS OF BONE QUALITY IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH DENOSUMAB	46
ABS0291 CLINICAL AND HEMODYNAMICS OUTCOMES PATIENTS WITH PULMONARY HYPERTENSION AND SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES	46
ABS0639 CLINICAL CHARACTERISTICS OF PHYSICAL FRAILTY IN PATIENTS WITH SYSTEMIC SCLEROSIS: AN ANALYSIS USING A JAPANESE SINGLE-CENTER COHORT	46
ABS0343 SUBCUTANEOUS ULTRA-LOW DOSE RITUXIMAB VERSUS INTRAVENOUS ULTRA-LOW DOSE RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL	45
OP0036 Artificial Intelligence Reinforced Social Robotics in Patient Communication for Patients with Rheumatic Diseases	45
OP0270 SENSITIVITY OF THE ACR/EULAR CLASSIFICATION CRITERIA IN A MULTICENTER ITALIAN COHORT OF PATIENTS WITH OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS): IMPLICATIONS FOR CLINICAL PRACTICE	45
ABS0950 ARTIFICIAL INTELLIGENCE ANALYSIS OF HRCT IMAGES REFLECTS PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE	45
POS0953 VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU'S ARTERITIS	45
POS1433 N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE (AcSDKP) IN RHEUMATOID ARTHRITIS: A NOVEL BIOMARKER FOR DISEASE ACTIVITY AND THERAPEUTIC MONITORING	45
ABS0357 EVALUATION OF THE UTILITY OF PHASE ANGLE IN THE DIAGNOSIS OF RHEUMATOID SARCOPENIA	44
ABS0542 PARAPROTEINEMIAS IN SJÖGREN'S DISEASE: ISOLATED MONOCLONAL GAMMOPATHY AND CRYOGLOBULINEMIA DEFINE TWO DISTINCT DISEASE PHENOTYPES	44
POS1458-HPR EFFECTIVENESS OF A BIOPSYCHOSOCIAL-BASED EXERCISE APPROACH ON PATIENT OUTCOMES IN PRIMARY SJÖGREN'S SYNDROME: A PRELIMINARY RANDOMIZED CONTROLLED TRIAL	43
ABS0060 UNDERSTANDING DRIVERS OF LUPUS PATHOGENESIS THROUGH COMPARISON OF PRECLINICAL MODELS	43
POS1216 EFFECT OF GENDER AND FOLLOW-UP TIME IN DAMAGE ACCRUAL: DATA FROM A LATIN AMERICA LUPUS COHORT	43
POS0704 LIPIDOMICS AND INFLAMMATION FOLLOWING DISEASE ONSET IN NEWLY DIAGNOSED RHEUMATOID ARTHRITIS: INSIGHTS FROM THE DESIGNA (DIETARY SIGNATURES IN ARTHRITIS) STUDY	43
ABS0310 IMPACT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES ON TNF INHIBITOR AND JAK INHIBITOR PRESCRIPTIONS IN RHEUMATOID ARTHRITIS: CROSS-SECTIONAL STUDIES FROM THE ART AND MAJIK REGISTRIES	43
POS1376 SPUTUM CALPROTECTIN LEVELS DO NOT ADD TO ABILITY OF SPUTUM ANTI-CCP AND RF TO PREDICT FUTURE DEVELOPMENT OF RA IN SERUM ANTI-CCP POSITIVE INDIVIDUALS AT-RISK FOR RA	42
POS0721 INTERPRETATION OF ANTI-NUCLEAR ANTIBODY INDIRECT IMMUNOFLUORESCENCE PATTERNS USING ARTIFICIAL INTELLIGENCE	42
ABS0110 INTEGRATIVE OMICS REVEALS MOLECULAR SIGNATURES DISTINGUISHING EARLY FROM ESTABLISHED RHEUMATOID ARTHRITIS AND PREDICTING CLINICAL RESPONSE	42
ABS0931 SLEEP QUALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON OF OBJECTIVE AND SUBJECTIVE SLEEP ASSESSMENT METHODS	42
POS0878 A PATIENT WITH MENTAL HEALTH DISORDER IN CONSULTATION: WHAT ARE THE ATTITUDES OF RHEUMATOLOGISTS	42
POS0228 PROTEIN PROFILING TO IDENTIFY INFLAMMATORY MARKERS ASSOCIATED WITH FERTILITY IN RA; AN EXPLORATORY STUDY	41
POS0695 SHIFT TOWARDS IgA EXPRESSION AND ABERRANT B CELL RECEPTOR SIGNALING RESPONSES IN DOUBLE NEGATIVE B CELLS FROM PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS	41
POS0242 MECHANICAL FORCES TRIGGER INVASIVE BEHAVIOUR IN SYNOVIAL FIBROBLASTS THROUGH N-CADHERIN/ADAM15-DEPENDENT MODULATION OF lncRNA H19 IN RHEUMATOID ARTHRITIS	41
POS1038 HIGH PREVALENCE OF INFLAMMATORY PsA-SPECIFIC FINDINGS IN PATIENTS WITH LONG-STANDING PSORIASIS BUT NO MUSCULOSKELETAL SYMPTOMS	41
ABS0750 FIRST USE OF NOVEL BCMA AND CD19 NANOBODY-BASED COMPOUND CAR-T THERAPY TO TARGET B-CELLS AND PLASMA CELLS IN PRECLINICAL STUDY OF AUTOIMMUNE DISEASES	40
ABS0439 PATH TO DIAGNOSIS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	40
POS0813 CAR T-CELL THERAPY IN SLE: A SYSTEMATIC/SCOPING REVIEW	40
ABS1200-HPR A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	40
POS1334 ACHIEVEMENT OF PROTEINURIA TARGETS =0.4 g/g IN LUPUS NEPHRITIS: A POST HOC ANALYSIS OF THE AURORA 1 STUDY OF VOCLOSPORIN	40
POS1511-HPR PHYSICAL FITNESS AND FUNCTIONAL CAPACITY IN CHILDREN AND ADOLESCENTS WITH JUVENILE DERMATOMYOSITIS	40
POS1091 Development and Validation of ‘Rheumatic ‘ - A Digital Symptom Checker for Confirmation and Prediction of Rheumatic Diseases: A Large-Scale Prospective Study	40
ABS0707 DO VARIATIONS OF THE 6-MINUTE WALK TEST ACCURATELY REFLECT CHANGES IN CARDIOPULMONARY COMPLICATIONS DURING THE FOLLOW-UP OF PATIENTS WITH SYSTEMIC SCLEROSIS	39
ABS0378 PROGRESSIVE OSSIFYING FIBRODYSPLASIA AS A VARIANT OF AXIAL SPONDYLOARTHRITIS WITH JUVENILE ONSET	39
POS1133 Upregulation of pro-survival receptors on antibody-secreting cells is linked to worse disease characteristics across SLE, Scleroderma and Sjögrens disease and offers potential new treatment an	39
ABS1158 ISOLATED ANTI-U1-RNP ANTIBODY DETECTED VIA PARTICLE-BASED MULTI-ANALYTE TECHNOLOGY (PMAT): CORRELATION OF TITRE INTENSITY WITH CONNECTIVE TISSUE DISEASES	38
POS1387 DYSREGULATED GENES AND IMMUNE CELL SHIFTS IN OSTEOARTHRITIS HIGHLIGHTING M0 MACROPHAGES, MMP9, AND MAST CELL ACTIVITY	38
ABS0368 SERUM FERRITIN AS A SPECIFIC BIOMARKER OF ANTI-MDA5-ILD: A MULTICENTER, CASE-CONTROL STUDY IN OBSERVATIONAL AND VALIDATION DATASETS	38
POS1206 CLINICAL AND FUNCTIONAL BENEFITS OF EARLY INTRA-ARTICULAR CORTICOSTEROID ADMINISTRATION FOR HIGH-RISK PERSISTENT POST-ARTHROSCOPIC SYNOVITIS	38
ABS0082 IDENTIFICATION OF CORONARY MORPHOLOGICAL DAMAGE IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES	37
ABS0462 REAL-WORLD OUTCOMES OF BARICITINIB MONOTHERAPY VERSUS csDMARD COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF EFFICACY, SAFETY, AND DRUG RETENTION	37
ABS1003 ARE MYOSITIS ANTIBODIES MORE COMMON THAN WE KNOW – VERY HIGH PREVALENCE OF ANTI-HMGCR ANTIBODY IN A SINGLE-CENTRE UK COHORT	37
POS0022 Long-Term Outcomes in IgA Vasculitis Nephritis Patients: Insights from the Croatian National Center	36
OP0333 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE	36
POS1158 ASSESSMENT OF MYOSITIS SPECIFIC ANTIBODIES IN A PRIMARY ARTHRITIS COHORT: SINGLE CENTRE PROSPECTIVE STUDY	35
POS0634 ASSOCIATION OF RADIOLOGICAL FINDINGS OF THE HAND WITH HAND FUNCTION AND AUTOANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS	35
POS0068 POLYGENIC RISK SCORES IMPROVE RISK ASSESSMENT OF CARDIOMETABOLIC COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS	35
POS0656 TOLERABILITY AND EFFICACY OF BMS-986353 (CC-97540), A CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY MANUFACTURED USING A NEXT-GENERATION PROCESS FOR SYSTEMIC SCLEROSIS: UPDATED	34
ABS0292 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: CLINICAL CHARACTERISTICS AND OUTCOMES. FIVE-YEAR EXPERIENCE	34
POS1311 VASCULAR EFFECTS OF ACHIEVING LOW DISEASE ACTIVITY IN AXIAL SPONDYLARTHRITIS - A 2-YEAR PROSPECTIVE COHORT STUDY	34
POS1402 NEXT GENERATION CAR-NK CELL THERAPY LEVERAGES ALLOIMMUNE DEFENSE TECHNOLOGY TO PERSIST WITHOUT CONDITIONING CHEMOTHERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASE	34
OP0081 Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database	34
POS0985 CROSS CULTURAL VALIDATION OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN LUPUS PATIENTS FROM LATIN AMERICA	34
ABS1173-HPR EVALUATION OF A PHARMACIST-LED MEDICATION ADHERENCE CLINIC FOR RHEUMATOLOGY PATIENTS PRESCRIBED DMARDS	34
OP0275 POTENTIAL DRUG TARGETS FOR CHRONIC WIDESPREAD PAIN: A PROTEOME-WIDE MENDELIAN RANDOMIZATION AND DRUG REPURPOSING ANALYSIS	34
ABS0290 LIFE SATISFACTION AND MEDICATION ADHERENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CROSS-SECTIONAL ANALYSIS OF ELLES COHORT BASELINE DATA	33
ABS0887 VASCULOPATHY RATHER THAN SKIN FIBROSIS AS A PREDICTOR OF HAND FUNCTION WORSENING IN SYSTEMIC SCLEROSIS PATIENTS	33
OP0180-HPR DOES FOLLOW-UP REALLY MATTER? A MIXED METHODS STUDY EXPLORING PATIENTS' PERSPECTIVES ON FOLLOW-UP SUPPORT IN REHABILITATION ACROSS LEVELS OF CARE	33
ABS1196-HPR HIGH REPORT OF SIDE-EFFECTS, AND ASSOCIATION OF PATIENTS' AGE WITH TOLERANCE OF SUBCUTANEOUS METHOTREXATE – TELEPHONE SURVEY RESULTS FROM A QUALITY IMPROVEMENT PROJECT	33
POS1460 MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN'S SYNDROME	33
OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY	33
POS0848 REAL-WORLD CLINICAL CHARACTERISTICS AND PATTERNS OF CARE IN ADULTS WITH SJÖGREN'S DISEASE DIAGNOSED BY RHEUMATOLOGISTS VS NON-RHEUMATOLOGISTS: RETROSPECTIVE ANALYSIS OF US ELECTRONIC HEALTH RE	33
POS1437 INTERSTITIAL ANCA-ASSOCIATED VASCULITIS ASSOCIATES WITH SEVERE KIDNEY INJURY INDEPENDENT OF GLOMERULONEPHRITIS	33
OP0200 ORAL DELIVERY OF DELTA-9-TETRAHYDROCANNABINOL PROVIDES SYMPTOM AND DISEASE MODIFICATION USING TWO MODELS OF KNEE OSTEOARTHRITIS	33
POS0128 TEN-YEAR ALL-CAUSE MORTALITY AND RISK FACTORS FOR DEATH IN A LARGE PROSPECTIVE REGISTRY COHORT OF IDIOPATHIC INFLAMMATORY MYOSITIS IN CHINA	32
OP0243 PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTIC	32
POS0042 HIGH-THROUGHPUT TRANSCRIPTOMIC PROFILING OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS CO-EXPRESSED GENE MODULES ASSOCIATED WITH RADIOGRAPHIC DAMAGE	32
OP0209 IMPACT OF CHRONIC INFLAMMATION AND COLLAGEN IV FRAGMENT CANSTATIN ON RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS AND ENDOTHELIAL CELL INTERACTIONS IN VITRO AND IN VIVO	32
POS0165 DETERMINATION OF DISTINCT PHENOTYPES OF PRIMARY SJÖGREN'S DISEASE USING CLUSTER ANALYSIS BASED ON CLINICAL AND BIOLOGICAL MANIFESTATIONS: DATA FROM 458 PATIENTS FROM THE PARIS SACLAY SJÖGREN'S	32
POS0253 FACTORS ASSOCIATED WITH TREATMENT PATHWAYS IN EARLY AXIAL SPONDYLOARTHRITIS: A MULTISTATE ANALYSIS OF THE 10-YEAR FOLLOW-UP OF THE DESIR COHORT	32
OP0110 SINGLE CELL RNA-SEQ DISSECTION OF THE SYNOVIAL FLUID IN PSORIATIC ARTHRITIS PATIENTS IDENTIFIES MYELOID CELL SUBSETS RELATED TO TREATMENT RESPONSE WITH BDMARDS	32
POS0215 CLASSIC VERSUS ATYPICAL POLYMYALGIA RHEUMATICA: TWO SIDES OF THE SAME COIN OR MISCLASSIFICATION?	32
POS0429 THE COMPLEMENT SYSTEM AND RESPONSE TO TNF INHIBITION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. POST HOC ANALYSIS FROM CONSUL, A LONGITUDINAL MULTI-CENTER RCT COHORT OF R-AXSPA-PAT	32